These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38361357)

  • 1. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
    Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
    Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
    Nijhof IS; Casneuf T; van Velzen J; van Kessel B; Axel AE; Syed K; Groen RW; van Duin M; Sonneveld P; Minnema MC; Zweegman S; Chiu C; Bloem AC; Mutis T; Lokhorst HM; Sasser AK; van de Donk NW
    Blood; 2016 Aug; 128(7):959-70. PubMed ID: 27307294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
    Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
    Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
    Chami B; Okuda M; Moayeri M; Pirenne F; Hidaka Y; Nambiar A; Song Z; Bedel O; Zhang B; Hopke J; Deng G; Zhu C; Macé S; Chiron M; Adrian F; Fukao T; Basile FG; Martin T
    Transfusion; 2022 Nov; 62(11):2334-2348. PubMed ID: 36239134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
    van de Donk NW; Janmaat ML; Mutis T; Lammerts van Bueren JJ; Ahmadi T; Sasser AK; Lokhorst HM; Parren PW
    Immunol Rev; 2016 Mar; 270(1):95-112. PubMed ID: 26864107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
    Shen F; Shen W
    Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
    Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
    Front Immunol; 2020; 11():1771. PubMed ID: 32922390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
    Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
    Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
    Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
    [No Abstract]   [Full Text] [Related]  

  • 12. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
    Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
    Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CD38
    Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
    Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isatuximab for the treatment of multiple myeloma.
    Goldsmith SR; Liu L; Covut F
    Drugs Today (Barc); 2021 Nov; 57(11):665-675. PubMed ID: 34821880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
    Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
    Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
    Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
    Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
    Díaz-Tejedor A; Rodríguez-Ubreva J; Ciudad L; Lorenzo-Mohamed M; González-Rodríguez M; Castellanos B; Sotolongo-Ravelo J; San-Segundo L; Corchete LA; González-Méndez L; Martín-Sánchez M; Mateos MV; Ocio EM; Garayoa M; Paíno T
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
    Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.